Clinical Epigenetics 2019
DOI: 10.1007/978-981-13-8958-0_6
|View full text |Cite
|
Sign up to set email alerts
|

The Role of Histone Variants in Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 85 publications
0
1
0
Order By: Relevance
“…ATRX acts with the histone chaperone DAXX to insert histone variant H3.3 (Nandakumar et al, 2017; Pritchard, 2019), and loss of ATRX leads to increased homologous recombination facilitating telomere destabilization and alternative lengthening of telomeres (ALT; Abedalthagafi et al, 2013; Dyer et al, 2017; Marinoni et al, 2014; Yuan et al, 2020). LoF mutations (1.7%) and copy loss (HD: 0.8%, 0 %; LoH: 20%, 0 %) were observed in AM at a similar frequency to CM, but are slightly more common in MM (3.7%), where they are associated with tumors of the lower anatomy (Broit et al, 2021) (Table 2).…”
Section: Resultsmentioning
confidence: 99%
“…ATRX acts with the histone chaperone DAXX to insert histone variant H3.3 (Nandakumar et al, 2017; Pritchard, 2019), and loss of ATRX leads to increased homologous recombination facilitating telomere destabilization and alternative lengthening of telomeres (ALT; Abedalthagafi et al, 2013; Dyer et al, 2017; Marinoni et al, 2014; Yuan et al, 2020). LoF mutations (1.7%) and copy loss (HD: 0.8%, 0 %; LoH: 20%, 0 %) were observed in AM at a similar frequency to CM, but are slightly more common in MM (3.7%), where they are associated with tumors of the lower anatomy (Broit et al, 2021) (Table 2).…”
Section: Resultsmentioning
confidence: 99%